Roche Holding AG (RHHVF)
Roche Holding AG operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Basel, CH. The stock last traded at $446.03, up 3.06% on the session, giving a market capitalisation of $307.28B. On trailing twelve-month figures it carries a trailing P/E of 23.46, a net margin of 20.3%. Its beta of 0.35 implies it has historically moved less than the broad market.
Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. The company's reach extends across key markets like Switzerland, Germany, and the United States, in addition to its broader international footprint. Its extensive pharmaceutical division develops and offers treatments for a diverse range of conditions. These therapeutic areas encompass critical fields such as oncology (cancer), neuroscience, infectious diseases, immunology, hemophilia, ophthalmology (eye care), dermatology (skin conditions), respiratory illnesses, anemia, inflammatory and autoimmune disorders, and transplantation. Beyond medicinal products, Roche is also a prominent supplier of in vitro diagnostic tests. These tests are vital for identifying numerous diseases, including various cancers, cardiovascular conditions, diabetes, COVID-19, hepatitis, and human papillomavirus (HPV). Complementing its testing services, the company provides the essential diagnostic instruments and chemical reagents necessary for these procedures. Demonstrating its commitment to innovation, Roche has established a research partnership with Synlogic, Inc. This collaboration aims to discover a novel synthetic biotic designed specifically for the treatment of inflammatory bowel disease (IBD). Tracing its origins back to its founding in 1896, Roche Holding AG is headquartered in Basel, Switzerland.
Roche Holding AG is most often compared with the following Healthcare names: